As regards the reliability of the information from the questionnaires, the overall quality of the responses was good and response rates of the individual questions were generally high. In cases of uncertainty responders were contacted by telephone in order to clarify responses. The present study has a few shortcomings. The response rate was not high, but is consistent with response rates of other questionnaire studies in stroke survivors. It is a retrospective study with a risk of recall bias. However, the reference group is assumed to be exposed to a similar bias, so it is unlikely that the retrospective character of the study would change the relative frequency of pain between the two groups. The pain prevalence before the study is not known and may therefore differ between the groups. The pain frequency increased from the primary questionnaire to the reminder in the stroke patients, but not in the reference group, implying that pain frequencies for stroke patients were not overrated in this study. Stroke severity has, in this and previous studies, been associated to pain prevalence. In this study, the included stroke patients were less severely affected than non-responders; however, the study group is likely to be representative for the stroke survivors. The pain intensity was not recorded for all subgroups of pain but only for headache and novel types of pain. In these two latter types of pain, there was no difference in pain intensity between stroke patients and reference subjects. What is of importance in a study like this may not be the pain intensity per se, but whether the pain has an intensity that needs daily medication. In this study 15% of stroke patients with novel pain after stroke took daily medication for their pains compared with 9% in the reference pain group. In conclusion, pain represents an important disability following stroke. In this population-based study, which included a sex and age-matched reference group, about 40% of the stroke patients had developed chronic pain within two years of their stroke and this pain was associated with depression and low age. Autoimmune uveitis is a sight-threatening intraocular inflammation driven by eye-invading autoreactive T-cells that cross the blood-retinal barrier. However, the majority of molecular pathomechanisms within the eye contributing to the onset of disease and to the loss of immune-privilege remain as yet unresolved. In order to understand the pathogenesis and the underlying molecular processes of autoimmune uveitis, different experimental animal models are NVP-BKM120 investigated. Among these, equine recurrent uveitis is the only spontaneous animal model for autoimmune uveitis, and ERU resembles closely the human disease in many clinical as well as immunopathological aspects. In contrast to the human disease, however, ERU is a frequent pathology in the equine population.